BANZEL
What it isSodium-channel blocker prolonging inactivation; seizures associated with Lennox-Gastaut syndrome.
Why this oneIt specifically reduces drop attacks, the seizure type most likely to cause traumatic injury in this syndrome.
What limits itQT shortening can be hazardous in short-QT syndromes; take with food, and valproate can substantially raise exposure.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Lennox-Gastaut syndrome (adjunctive) | Pediatric 1–<17 yr | 10 mg/kg/day in 2 divided doses | — | 45 mg/kg/day (<=3200 mg/day) BID |
| Lennox-Gastaut syndrome (adjunctive) | Adults >=17 yr | 400–800 mg/day in 2 divided doses | — | 3200 mg/day BID |
Titration Increase every other day (by ~10 mg/kg/day in children; by 400–800 mg/day in adults).
Renal Hemodialysis reduces exposure ~30%; consider dose adjustment around dialysis. No specific adjustment otherwise.
Hepatic Not studied; not recommended in severe impairment; use caution in mild-moderate impairment.
Pregnancy Pregnancy exposure registry available; encourage enrollment of patients exposed during pregnancy.
Lactation Undefined
NO BOXED WARNINGS
Principal riskQT shortening; valproate raises levels
Cost, est. cash$10–$300/month
Generic entry2016
Legacy pregnancy categoryC
Defining liabilitySedation, dizziness and agent-specific rash, behavioral, hepatic, hematologic or teratogenic toxicity.

Open Rufinamide in the interactive console ↗

